Type I Interferon: Potential Therapeutic Target for Psoriasis?

• Yihong Yao ,

  * E-mail: YaoY@MedImmune.com

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Laura Richman,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Chris Morehouse,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Melissa de los Reyes,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Brandon W. Higgs,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Anmarie Boutrin,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Barbara White,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Anthony Coyle,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• James Krueger,

  Affiliation Center for Clinical and Translational Science, Rockefeller University, New York, New York, United States of America

  ⨯
• Peter A. Kiener,

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯
• Bahija Jallal

  Affiliation MedImmune, Inc., Gaithersburg, Maryland, United States of America

  ⨯